Letter to the editor
Systemic exposure to fluticasone MDI delivered through antistatic chambers

https://doi.org/10.1016/j.jaci.2011.06.014Get rights and content

First page preview

First page preview
Click to open first page preview

References (9)

There are more references available in the full text version of this article.

Cited by (7)

  • Inhaled corticosteroids in children: Effects on bone mineral density and growth

    2014, The Lancet Respiratory Medicine
    Citation Excerpt :

    The disparate effects on growth reported in these studies are probably due to dose differences; findings from a pharmacokinetic and bioavailability study45 comparing delivery of fluticasone propionate by Aerochamber and Babyhaler in infants aged 1–3 years showed that the Aerochamber delivered a two times higher dose than did the Babyhaler.45 These differences in delivery of inhaled corticosteroids in infants might be even larger with the use of antistatic valved holding chambers; a recent study showed significantly increased steady-state concentrations of fluticasone propionate for use with an antistatic Aerochamber with facemask compared with labelling claims.46 Two studies47,48 assessed the use of intermittent high-dose inhaled corticosteroids for infants who had a history of severe exacerbations needing oral corticosteroids associated with upper-respiratory-tract infections but were asymptomatic between episodes.

  • Advances in pediatric asthma in 2011: Moving forward

    2012, Journal of Allergy and Clinical Immunology
    Citation Excerpt :

    Linear growth was not significantly different in those children; however, post hoc analysis revealed that children who are younger in age and of lesser weight relative to the entire cohort had significantly less linear growth. In addition, Elmallah et al58 reported increased systemic exposure of ICSs with the use of an antistatic valved holding chamber compared with a conventional (static) chamber and recommended initiation of a lower-dose ICS or a reduction in the dose as asthma control is achieved. In regard to combination therapy, a recent review by the US Food and Drug Administration indicated concern regarding increased risk of LABA therapy and suggested that further studies are needed to see whether combination ICS/LABA therapy administered in a single device reduces such risk.59

  • Inhaled corticosteroids in lung diseases

    2013, American Journal of Respiratory and Critical Care Medicine
View all citing articles on Scopus

At the time of this study, Dr Khan was a Fellow in the College of Pharmacy at the University of Florida.

This study was supported in part by an investigator-initiated grant from GlaxoSmithKline and NIH Research Facilities Construction Program C06, grant RR17568. Dr Shuster is supported by NIH General Clinical Research Center grants M01RR00082 and U54RR025208.

Disclosure of potential conflict of interest: L. Hendeles received compensation for travel expenses from Monaghan Medical, once in 2009 and once in 2011, for presentation of papers at scientific meetings. The rest of the authors have declared that they have no conflict of interest.

View full text